Guideline-Directed Medical Therapy Attainment and Outcomes in Dialysis-Requiring Versus Nondialysis Chronic Kidney Disease in the ISCHEMIA-CKD Trial. Issue 10 (4th October 2022)

• Record Type: Journal Article
• Authors: Mathew, Roy O.; Maron, David J.; Anthopolos, Rebecca; Fleg, Jerome L.; O'Brien, Sean M.; Rockhold, Frank W.; Briguori, Carlo; Roik, Marek F.; Mazurek, Tomasz; Demkow, Marcin; Malecki, Robert; Ye, Zhiming; Kaul, Upendra; Miglinas, Marius; Stone, Gregg W.; Wald, Ron; Charytan, David M.; Sidhu, Mandeep S.; Hochman, Judith S.; Bangalore, Sripal
• Is Part Of: Circulation. Volume 15:Issue 10(2022)
• Page Start: e008995
• Publication Date: 2022-10-04
• Subjects: cardiovascular diseases -- clinical trial -- lipoproteins -- kidney -- secondary prevention; Cardiovascular system -- Diseases -- Treatment -- Periodicals; Cardiovascular system -- Diseases -- Research -- Periodicals; Outcome assessment (Medical care) -- Periodicals; Evidence-based medicine -- Periodicals; 616.1007
• DOI: 10.1161/CIRCOUTCOMES.122.008995
• Languages: English
• ISSNs: 1941-7713

Abstract

Abstract : Background: Patients with chronic kidney disease (CKD) on dialysis (CKD G5D) have worse cardiovascular outcomes than patients with advanced nondialysis CKD (CKD G4-5: estimated glomerular filtration rate <30 mL/[min·1.73m 2 ]). Our objective was to evaluate the relationship between achievement of cardiovascular guideline-directed medical therapy (GDMT) goals and clinical outcomes for CKD G5D versus CKD G4-5. Methods: This was a subgroup analysis of ISCHEMIA-CKD (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches—Chronic Kidney Disease) participants with CKD G4-5 or CKD G5D and moderate-to-severe myocardial ischemia on stress testing. Exposures included dialysis requirement at randomization and GDMT goal achievement during follow-up. The composite outcome was all-cause mortality or nonfatal myocardial infarction. Individual GDMT goal (smoking cessation, systolic blood pressure <140 mm Hg, low-density lipoprotein cholesterol <70 mg/dL, statin use, aspirin use) trajectory was modeled. Percentage point difference was estimated for each GDMT goal at 24 months between CKD G5D and CKD G4-5, and for association with key predictors. Probability of survival free from all-cause mortality or nonfatal myocardial infarction by GDMT goal achieved was assessed for CKD G5D versus CKD G4-5. Results: A total of 415 CKD G5D and 362 CKD G4-5 participants were randomized. Participants with CKD G5D were less likely to receive statin (–6.9% [95% CI, –10.3% to –3.7%]) and aspirin therapy (−3.0% [95% CI, −5.6% to −0.6%]), with no difference in other GDMT goal attainment. Cumulative exposure to GDMT achieved during follow-up was associated with reduction in all-cause mortality or nonfatal myocardial infarction (hazard ratio, 0.88 [95% CI, 0.87–0.90]; per each GDMT goal attained over 60 days), irrespective of dialysis status. Conclusions: CKD G5D participants received statin or aspirin therapy less often. Cumulative exposure to GDMT goals achieved was associated with lower incidence of all-cause mortality or nonfatal myocardial infarction in participants with advanced CKD and chronic coronary disease, regardless of dialysis status. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01985360.